Stuart Neil

List of Publications by Year in Descending Order

84 papers	7,493 citations	40 h-index	86 g-index
87 ext. papers	9,030 ext. citations	12.2 avg, IF	6.09 L-index

#	Paper	IF	Citations
84	Disrupted Peyer's Patch Microanatomy in COVID-19 Including Germinal Centre Atrophy Independent of Local Virus.. *Frontiers in Immunology*, **2022**, 13, 838328	8.4	1
83	Homebrew: an economical and sensitive glassmilk-based nucleic-acid extraction method for SARS-CoV-2 diagnostics.. *Cell Reports Methods*, **2022**, 100186		1
82	Homebrew: Protocol for glassmilk-based nucleic-acid extraction for SARS-CoV-2 diagnostics.. *STAR Protocols*, **2022**, 3, 101300	1.4	0
81	TRIM25 and ZAP target the Ebola virus ribonucleoprotein complex to mediate interferon-induced restriction.. *PLoS Pathogens*, **2022**, 18, e1010530	7.6	0
80	TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction. *PLoS Pathogens*, **2021**, 17, e1009820	7.6	2
79	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. *Nature Microbiology*, **2021**, 6, 1433-1442	26.6	32
78	S-farnesylation is essential for antiviral activity of the long ZAP isoform against RNA viruses with diverse replication strategies. *PLoS Pathogens*, **2021**, 17, e1009726	7.6	6
77	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation **2021**,		15
76	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. *PLoS ONE*, **2021**, 16, e0249791	3.7	3
75	The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2. *Journal of Virology*, **2021**, 95,	6.6	63
74	More than the Eye Can See: Shedding New Light on SARS-CoV-2 Lateral Flow Device-Based Immunoassays. *ACS Applied Materials & Interfaces*, **2021**, 13, 25694-25700	9.5	3
73	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. *Immunity*, **2021**, 54, 1276-1289.e6	32.3	60
72	Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections **2021**,		5
71	Minimal impact of ZAP on lentiviral vector production and transduction efficiency. *Molecular Therapy - Methods and Clinical Development*, **2021**, 23, 147-157	6.4	
70	Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. *Lancet Microbe, The*, **2021**, 2, e461-e471	22.2	31
69	Targeted Restriction of Viral Gene Expression and Replication by the ZAP Antiviral System. *Annual Review of Virology*, **2021**, 8, 265-283	14.6	10
68	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation. *PLoS ONE*, **2021**, 16, e0256813	3.7	11

67	The origins of SARS-CoV-2: A critical review. *Cell*, **2021**, 184, 4848-4856	56.2	103
66	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. *Journal of Infection*, **2020**, 81, 931-936	18.9	32
65	Fake Science: XMRV, COVID-19, and the Toxic Legacy of Dr. Judy Mikovits. *AIDS Research and Human Retroviruses*, **2020**, 36, 545-549	1.6	6
64	Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. *Analyst, The*, **2020**, 145, 5638-5646	5	14
63	HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 T Cells. *Journal of Virology*, **2020**, 94,	6.6	10
62	Translational Research in the Time of COVID-19-Dissolving Boundaries. *PLoS Pathogens*, **2020**, 16, e1008898	7.8	1
61	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nature Microbiology*, **2020**, 5, 1598-1607	26.6	667
60	SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans. *MBio*, **2020**, 11,	7.8	60
59	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. *PLoS Pathogens*, **2020**, 16, e1008817	7.6	72
58	Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Nature Medicine*, **2020**, 26, 1701-1707	50.5	170
57	CpG Dinucleotides Inhibit HIV-1 Replication through Zinc Finger Antiviral Protein (ZAP)-Dependent and -Independent Mechanisms. *Journal of Virology*, **2020**, 94,	6.6	38
56	Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses. *MBio*, **2019**, 10,	7.8	4
55	KHNYN is essential for the zinc finger antiviral protein (ZAP) to restrict HIV-1 containing clustered CpG dinucleotides. *ELife*, **2019**, 8,	8.9	66
54	Adeno-associated virus Rep proteins antagonize phosphatase PP1 to counteract KAP1 repression of the latent viral genome. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E3529-E3538	11.5	8
53	HLA-C downregulation by HIV-1 adapts to host HLA genotype. *PLoS Pathogens*, **2018**, 14, e1007257	7.6	14
52	The Envelope Gene of Transmitted HIV-1 Resists a Late Interferon Gamma-Induced Block. *Journal of Virology*, **2017**, 91,	6.6	20
51	Exercising Restraint. *Cell Host and Microbe*, **2017**, 21, 274-277	23.4	0
50	A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection. *Scientific Reports*, **2017**, 7, 1057	4.9	9

49	Sensitivity to BST-2 restriction correlates with Orthobunyavirus host range. *Virology*, **2017**, 509, 121-130	3.6	5
48	Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane. *Frontiers in Immunology*, **2017**, 8, 1853	8.4	15
47	HIV-1 Vpu Mediates HLA-C Downregulation. *Cell Host and Microbe*, **2016**, 19, 686-95	23.4	81
46	Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. *Cell Host and Microbe*, **2016**, 20, 429-442	23.4	115
45	Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef. *Cell Host and Microbe*, **2015**, 18, 409-23	23.4	118
44	G2/M cell cycle arrest correlates with primate lentiviral Vpr interaction with the SLX4 complex. *Journal of Virology*, **2015**, 89, 230-40	6.6	31
43	Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors. *PLoS Pathogens*, **2015**, 11, e1005141	7.6	43
42	The sheep tetherin paralog oBST2B blocks envelope glycoprotein incorporation into nascent retroviral virions. *Journal of Virology*, **2015**, 89, 535-44	6.6	6
41	Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses. *Journal of Virology*, **2014**, 88, 5845-58	6.6	21
40	Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. *PLoS Pathogens*, **2014**, 10, e1003895	7.6	44
39	Retroviral retention activates a Syk-dependent HemITAM in human tetherin. *Cell Host and Microbe*, **2014**, 16, 291-303	23.4	40
38	Evidence for IFN□nduced, SAMHD1-independent inhibitors of early HIV-1 infection. *Retrovirology*, **2013**, 10, 23	3.6	49
37	The antiviral activities of tetherin. *Current Topics in Microbiology and Immunology*, **2013**, 371, 67-104	3.3	74
36	Ig-like transcript 7, but not bone marrow stromal cell antigen 2 (also known as HM1.24, tetherin, or CD317), modulates plasmacytoid dendritic cell function in primary human blood leukocytes. *Journal of Immunology*, **2013**, 190, 2622-30	5.3	30
35	The UBAP1 subunit of ESCRT-I interacts with ubiquitin via a SOUBA domain. *Structure*, **2012**, 20, 414-28	5.2	76
34	Innate sensing of HIV-1 assembly by Tetherin induces NFB-dependent proinflammatory responses. *Cell Host and Microbe*, **2012**, 12, 633-44	23.4	218
33	A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. *PLoS Pathogens*, **2012**, 8, e1002609	7.6	79
32	SIV envelope acquires a nefarious habit. *Cell Host and Microbe*, **2011**, 9, 3-5	23.4	

31	Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. *Retrovirology*, **2011**, 8, 16	3.6	59
30	Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. *Journal of Virology*, **2011**, 85, 9737-48	6.6	32
29	Host factors involved in retroviral budding and release. *Nature Reviews Microbiology*, **2011**, 9, 519-31	22.2	145
28	Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. *Viruses*, **2011**, 3, 520-40	6.2	62
27	Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. *Journal of Virology*, **2010**, 84, 12958-70	6.6	107
26	Identification of a receptor for an extinct virus. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 19496-501	11.5	17
25	Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5166-71	11.5	80
24	The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. *PLoS Pathogens*, **2010**, 6, e1000843	7.6	113
23	Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. *Journal of Virology*, **2010**, 84, 12185-99	6.6	145
22	Vpu, Tetherin and Innate Immunity: Antiviral Restriction of Retroviral Particle Release **2010**, 271-305		
21	Human immunodeficiency virus, restriction factors, and interferon. *Journal of Interferon and Cytokine Research*, **2009**, 29, 569-80	3.5	106
20	Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. *Journal of Virology*, **2009**, 83, 11966-78	6.6	234
19	Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. *Journal of Virology*, **2009**, 83, 1837-44	6.6	319
18	Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. *PLoS Pathogens*, **2009**, 5, e1000300	7.6	246
17	Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. *Nature*, **2008**, 451, 425-30	50.4	1369
16	Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. *Cell Host and Microbe*, **2008**, 4, 52-62	23.4	143
15	An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. *Cell Host and Microbe*, **2007**, 2, 193-203	23.4	208
14	Plasma membrane is the site of productive HIV-1 particle assembly. *PLoS Biology*, **2006**, 4, e435	9.7	269

13	HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. *PLoS Pathogens*, **2006**, 2, e39	7.6	211
12	Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. *Journal of General Virology*, **2006**, 87, 411-418	4.9	25
11	HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation. *Blood*, **2005**, 105, 4693-9	2.2	48
10	An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. *Journal of Virology*, **2005**, 79, 9410-8	6.6	31
9	The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. *Journal of Virology*, **2005**, 79, 9618-24	6.6	61
8	Lv2, a novel postentry restriction, is mediated by both capsid and envelope. *Journal of Virology*, **2004**, 78, 2006-16	6.6	49
7	Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. *Molecular Therapy*, **2002**, 5, 269-74	11.7	33
6	Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. *Journal of Virology*, **2001**, 75, 5448-56	6.6	115
5	Transcytosis and surface presentation of IL-8 by venular endothelial cells. *Cell*, **1997**, 91, 385-95	56.2	671
4	The P681H mutation in the Spike glycoprotein confers Type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant		6
3	KHNYN is essential for ZAP-mediated restriction of HIV-1 containing clustered CpG dinucleotides		1
2	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 transmission identifies community social distancing as the dominant intervention reducing outbreaks		3
1	The polybasic cleavage site in the SARS-CoV-2 spike modulates viral sensitivity to Type I IFN and IFITM2		3